Immunotherapy and the Future of Oncology - Breakthroughs, Barriers, and the Road Ahead

Description

#Immunotherapy #Oncology #CancerTreatment #HealthcareInvestment #biotech Cancer immunology has been a growth area over the last decade, with a couple of blockbuster drugs from from Merck (Keytruda) which did 25 billion dollars of sales 2 years ago, and Bristol Meyers Squibb (Opdivo) another big one, and several smaller copycat versions. There are many more cancer immunotherapy drugs coming along the way, and there's a huge amount of growth to come in the sector. We've got an excellent panel with us to discuss what cancer immunotherapy is, we'll be discussing the market and how it will evolve, and we'll be looking at how investors can make money from it. We are joined by Dr Martin Kaiser: Professor Kaiser is the consultant Haematologist at the Royal Marsden and a clinical scientist at the Institute of Cancer Research. Jeremy Skillington is the CEO at AIM-listed Poolbeg Pharma, and Dr Brian White is an experienced Healthcare Analyst at Shore Capital. Filmed on the 13th August 2025.